Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/11436
Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide.
Muzzi, Alessandro | Brozzi, Alessandro | Serino, Laura | Bodini, Margherita | Abad, Raquel ISCIII | Caugant, Dominique | Comanducci, Maurizio | Lemos, Ana Paula | Gorla, Maria Cecilia | Křížová, Pavla | Mikula, Claudia | Mulhall, Robert | Nissen, Michael | Nohynek, Hanna | Simões, Maria João | Skoczyńska, Anna | Stefanelli, Paola | Taha, Muhamed-Kheir | Toropainen, Maija | Tzanakaki, Georgina | Vadivelu-Pechai, Kumaran | Watson, Philip | Vazquez-Moreno, Julio Alberto ISCIII | Rajam, Gowrisankar | Rappuoli, Rino | Borrow, Ray | Medini, Duccio
Vaccine . 2019 Feb 8;37(7):991-1000.
The Meningococcal Antigen Typing System (MATS) was developed to identify meningococcus group B strains with a high likelihood of being covered by the 4CMenB vaccine, but is limited by the requirement for viable isolates from culture-confirmed cases. We examined if antigen genotyping could complement MATS in predicting strain coverage by the 4CMenB vaccine. From a panel of 3912 MATS-typed invasive meningococcal disease isolates collected in England and Wales in 2007-2008, 2014-2015 and 2015-2016, and in 16 other countries in 2000-2015, 3481 isolates were also characterized by antigen genotyping. Individual associations between antigen genotypes and MATS coverage for each 4CMenB component were used to define a genetic MATS (gMATS). gMATS estimates were compared with England and Wales human complement serum bactericidal assay (hSBA) data and vaccine effectiveness (VE) data from England. Overall, 81% of the strain panel had genetically predictable MATS coverage, with 92% accuracy and highly concordant results across national panels (Lin's accuracy coefficient, 0.98; root-mean-square deviation, 6%). England and Wales strain coverage estimates were 72-73% by genotyping (66-73% by MATS), underestimating hSBA values after four vaccine doses (88%) and VE after two doses (83%). The gMATS predicted strain coverage in other countries was 58-88%. gMATS can replace MATS in predicting 4CMenB strain coverage in four out of five cases, without requiring a cultivable isolate, and is open to further improvement. Both methods underestimated VE in England. Strain coverage predictions in other countries matched or exceeded England and Wales estimates.
Genotype | Antigens, Bacterial | Genotyping Techniques | Global Health | Humans | Meningitis, Meningococcal | Meningococcal Vaccines | Molecular Epidemiology | Neisseria meningitidis, Serogroup B